My Mother Had Alzheimer’s. That’s Why I Started a GLP-1 at 48
An endocrinologist recently made a significant personal health decision that highlights the evolving view of GLP-1 medications. Dr. Caroline Messer, who spent her career treating patients with these drugs, has begun taking them herself. However, her motivation is not weight loss. Instead, she is acting on a desire to potentially mitigate the risk of Alzheimer’s disease, a condition that took her mother’s memory and independence at a young age.
While the medical community has no definitive proof that GLP-1 therapy prevents dementia in humans, Dr. Messer points to a growing body of research. Studies show that GLP-1 receptors exist throughout the brain, and early data suggest these medications might reduce neuroinflammation, improve insulin signaling, and support blood-brain barrier function. While observational studies indicate lower dementia rates among patients with diabetes treated with these drugs, she acknowledges that such findings do not establish direct causality. Clinical trials are still in their early stages, and results remain mixed.
Dr. Messer chose orforglipron for her personal protocol, noting its structure as a small molecule rather than a large peptide. She suggests that this molecular size may allow for different tissue distribution compared to traditional injectable options. She emphasizes that this is a personal decision based on her family history and risk tolerance rather than a recommendation for the general population.
Even if the potential link to dementia prevention does not hold up to long-term scrutiny, Dr. Messer views the decision through a wider lens of metabolic health. GLP-1 medications already show promise in areas like cardiovascular health, kidney function, and systemic inflammation reduction. For a physician who witnessed the decline of a parent, the choice is about weighing potential long-term upside against current medical uncertainty. She continues to focus on lifestyle factors like protein intake and strength training while observing the science as it develops over the coming years.